UNIV SERVICES AGREEMENT - JOHN HOPKINS U

ALL 3 ARE FROM THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY. THE FIRST TWO PROJECTS EVALUATE THE ABORTIFACIENT ACTIVITY OF PROSTAGLANDIN F2A IN THE FIRST TRIMESTER AND THE SECOND TRIMESTER RESPECTIVELY. THREE MODES OF ADMININSTRATION WERE TESTED. TO DATE, OVER 30 PATIENTS HAVE RECEIVED PROSTAGLANDIN INTRAVENOUSLY, 21 INTRAVAGINALLY AND OVER 60 BY THE INTRA-AMNIOTIC ROUTE OF ADMINISTRATION. THE LATER METHOD APPEARS TO BE THE MOST FAVORABLE FOR IMMEDIATE UTILIZATION. THE THIRD PROJECT DEALTH WITH THE CLINICAL EFFICACY OF PROSTAGLANDIN F2A AS A LUTEOLYTIC AGENT IN THE NONPREGNANT HUMAN. IN GENERAL, THERE WERE NO SIGNIFICANT DIFFERENCES BETWEEN THE CONTROL CYCLE AND THE INFUSION CYCLE.